Seoul St. Mary’s Hospital Performs Korea’s First LLAMACORN Procedure For Repeat TAVI – 뉴스1

Seoul St. Mary’s Hospital has performed Korea’s first LLAMACORN procedure for a repeat transcatheter aortic valve implantation (TAVI). This milestone offers new hope for patients requiring repeat valve procedures and highlights advancements in minimally invasive cardiac surgery in Korea.

The procedure was carried out on a patient who previously underwent TAVI and needed a repeat intervention due to valve degeneration. The hospital confirmed that the operation was successful and marked a breakthrough in applying the LLAMACORN device for repeat TAVI procedures in Korea.

According to hospital officials, this is the first documented case of using the LLAMACORN system for a repeat TAVI in Korea, demonstrating the device’s potential to improve outcomes for high-risk patients. The surgery was performed by a multidisciplinary team of cardiologists and cardiac surgeons, utilizing advanced imaging and minimally invasive techniques.

Impact of Korea’s First LLAMACORN Repeat TAVI

This development is significant because it expands the options for patients needing repeat valve procedures, especially those at high surgical risk. The successful use of the LLAMACORN device could lead to broader adoption across Korea and potentially improve patient outcomes by reducing complications associated with open-heart surgery.

Experts suggest that this milestone may accelerate the adoption of innovative transcatheter valve technologies in Korea, aligning with global trends toward less invasive cardiac interventions.

Background on Repeat TAVI Procedures in Korea

Transcatheter aortic valve implantation (TAVI) has become a common alternative to open-heart surgery for treating aortic stenosis, especially among high-risk patients. However, repeat TAVI procedures are complex due to anatomical changes and device limitations.

Until now, Korea has lacked documented cases of using the LLAMACORN system for repeat TAVI, which has been more widely adopted in Western countries. The successful procedure at Seoul St. Mary’s Hospital indicates a shift toward more advanced, minimally invasive options for complex cases.

“This is a landmark case for Korea. The successful implementation of the LLAMACORN system for a repeat TAVI opens new possibilities for high-risk patients who previously had limited options.”

— Dr. Kim Jae-hyun, Cardiologist at Seoul St. Mary’s Hospital

Unanswered Questions About Long-Term Outcomes

It is not yet clear how the long-term durability and safety of the LLAMACORN device for repeat TAVI will compare to traditional methods. Further follow-up and additional cases are needed to assess the broader applicability and potential complications.

Next Steps for Broader Adoption and Research

Seoul St. Mary’s Hospital plans to monitor the patient closely and publish detailed results. Other Korean hospitals may begin adopting the LLAMACORN system for similar cases, pending further evidence of safety and efficacy. Clinical trials or larger case series are likely to follow to establish best practices.

Key Questions

What is the LLAMACORN device used for?

The LLAMACORN device is used for transcatheter aortic valve implantation (TAVI), particularly in complex cases such as repeat procedures or high-risk patients.

Why is repeat TAVI challenging?

Repeat TAVI is challenging due to anatomical changes, potential device interference, and increased risk of complications compared to initial procedures.

How does this development impact Korean cardiac care?

This milestone signifies Korea’s advancement in minimally invasive cardiac procedures and could improve treatment options for high-risk patients needing repeat interventions.

Are there risks associated with the LLAMACORN system?

As with all medical procedures, risks exist and include device malfunction or complications, but further research is needed to assess long-term safety for repeat TAVI cases.

Source: local